AstraZeneca PLC
AZN
$77.96
$0.710.92%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 14.89B | 13.57B | 12.94B | 12.68B | 12.02B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.89B | 13.57B | 12.94B | 12.68B | 12.02B |
| Cost of Revenue | 2.81B | 2.46B | 2.17B | 2.20B | 2.08B |
| Gross Profit | 12.08B | 11.10B | 10.77B | 10.48B | 9.94B |
| SG&A Expenses | 5.16B | 4.74B | 5.02B | 4.53B | 3.79B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -40.00M | -25.00M | -60.00M | -65.00M | -70.00M |
| Total Operating Expenses | 11.51B | 10.25B | 10.04B | 9.37B | 8.68B |
| Operating Income | 3.38B | 3.32B | 2.90B | 3.31B | 3.34B |
| Income Before Tax | 1.67B | 1.83B | 2.40B | 2.80B | 897.00M |
| Income Tax Expenses | 166.00M | 395.00M | 469.00M | 620.00M | -62.00M |
| Earnings from Continuing Operations | 1.50B | 1.43B | 1.93B | 2.18B | 959.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00 | -4.00M | -1.00M | -1.00M | 1.00M |
| Net Income | 1.50B | 1.43B | 1.93B | 2.18B | 960.00M |
| EBIT | 3.38B | 3.32B | 2.90B | 3.31B | 3.34B |
| EBITDA | 4.20B | 4.63B | 4.15B | 4.57B | 4.23B |
| EPS Basic | 0.97 | 0.92 | 1.24 | 1.41 | 0.62 |
| Normalized Basic EPS | 1.24 | 1.22 | 1.03 | 1.21 | 1.23 |
| EPS Diluted | 0.96 | 0.91 | 1.24 | 1.40 | 0.61 |
| Normalized Diluted EPS | 1.23 | 1.21 | 1.02 | 1.20 | 1.22 |
| Average Basic Shares Outstanding | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B |
| Average Diluted Shares Outstanding | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B |
| Dividend Per Share | 2.10 | 0.00 | 1.00 | -- | 1.97 |
| Payout Ratio | -- | 110.29% | 0.88% | 139.19% | 1.25% |
